Comparison
Semaglutid vs. Thymosin Alpha-1
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
910463-68-2
62304-98-7
Molecular weight
4113.6 g/mol
3108.32 g/mol
Half-life
165 h
2 h
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerAc-SDAAVDTSSEITTKDLKEKKEVVEEAENMechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Thymosin Alpha-1
Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
2
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
5
1